創薬

免疫療法は精密腫瘍学を推進していますが、既存の免疫腫瘍学治療がすべての患者に有効なわけではありません。トランスレーショナルリサーチの現状に関する私たちのレビューでは、臨床試験において有望な結果を示している標的や治療法が明らかになっています。

過去5年間の世界の製薬特許データは、この分野が根本的な転換期にあることを示しています。治療プラットフォームは多様化し、分子標的は従来のタンパク質を大きく超えて拡大しており、疾患の焦点もこれまで治療困難とされていた領域へとシフトしています。これらのパターンは、イノベーションがどこに集中しているかだけでなく、

環状ペプチドは、経口投与法の改善に伴い、がん、炎症性疾患、感染症などの治療を向上させています。

スピロ[2.3]ヘキサンは、新規薬物化合物の有望かつ挑戦的な足場構造の一例です。CAS BioFinderを用いた人工知能による予測分析を活用することで、研究者は検証対象となる候補をより効率的に特定しました。

CAS hosted Life Sciences Summits across three regions in 2025, exploring practical AI integration in drug discovery. Learn about data governance, implementation barriers, and modality-specific challenges.

マイクロバイオームのブレイクスルーからAIを活用したシミュレーションまで、このCAS Insightsウェビナーのまとめでは、製薬研究を形作る最新の創薬トレンドを探ります。

核医学のセラノスティクスというアプローチは、診断と治療に同一の薬剤を用いることで「見て、治療する」がん治療を可能にします。これらの精密治療が初期段階のケアへと移行するにつれ、2024年の投資額は3倍の148億6,000万ドルにまで増加しました。

がん治療の改善、神経変性疾患の特定、さらには将来のパンデミックへの備えなどを可能にする、創薬における8つの主要なトレンドを探ります。

多くの触媒や試薬は湿気に敏感であるため、水は潜在的な溶媒として除外されることがよくありました。しかし現在では、有害な化学物質や揮発性有機化合物を溶媒として使用することなく、水中または水上で多くの有機変換反応を実現できることが明らかになっています。

MAIT細胞は他の非従来型T細胞と比べて比較的新しい発見であり、研究者たちはこれを「off-the-shelf（汎用型）」の免疫療法として応用する方向で研究を進めています。

幹細胞治療は糖尿病を治せる可能性がある

ナノスケールの薬物送達システムの進歩は、現在のマイクロRNA治療における課題に対処しており、より広く活用される送達手法となる可能性がある。

脂質ベースのDDSに関する新しいレポートをプレビュー

mRNAワクチンはCOVID-19以外の病気との戦いにどのように役立つことができるでしょうか？

減量のためのGLP-1受容体作動薬およびGIPポリペプチド薬に関する詳細をまとめたインフォグラフィック。

低分子PPI阻害剤は、がん治療を改善する直前の段階にあります

PROTACは、がんや神経変性疾患などの治療に向けた低分子医薬品開発を加速させています

業界のリーダーたちとの対談を通じて、CASが高度なデータ管理と予測モデルを活用し、どのように創薬に革命をもたらしているかをご紹介します。

CAR-T細胞療法は主にがん治療に用いられてきましたが、自己免疫疾患やHIVなどの治療においても有望な結果が示されています

GIPおよびGLP-1の機能が、心血管疾患および神経変性疾患の治療において有望な結果を示している。

Nanoscale drug delivery systems can improve treatment for cancer, autoimmune diseases, HIV, and other conditions

薬剤リポジショニング、細胞療法、遺伝子療法を含む併用療法が、いかに希少疾患の治療改善につながっているか。

Dr. Zoheb Hassan, a senior consultant at Frost & Sullivan, shares his insights on the data management complexities that define the current drug discovery landscape.

Biomarkers, personalized medicine and gene therapies are fueling research breakthroughs. Discover new treatments targeting genetics and protein buildup to manage this devastating disease.

Different types of antisense oligonucleotide therapies, such as exosomes and nanoparticles, offering new hope in genetic medicine.

While no cure exists for PolyQ diseases like Huntington's, new breakthroughs, therapies, and research could change that.

Immunotherapy is advancing with new approaches like CAR-T cell therapy, antibody-drug conjugates, and even checkpoint inhibitors.

Immuno-oncology has the potential to treat cancer without sacrificing the patient's wellbeing.

Covalent inhibitors were once avoided due to negative side effects, but new drugs have changed the landscape.

More than 100 antibody-drug conjugates are in clinical trials. These therapeutics combine the targeting abilities of antibodies with the power of chemotherapy to change cancer treatment.

2018年以降、がんとの闘いにおける可能性から、抗体薬物複合体に関する研究への関心が飛躍的に増加しています。

We talk with Jefferson Parker of NullSet Informatics Solutions, about sequence analysis for drug discovery and the frontiers for AI in computational biology.

Induced-proximity target protein degradation (TPD) is a ground-breaking strategy in drug discovery that has emerged recently.

We chat with Ben Taft, Sr. Director of Chemistry at Via Nova Therapeutics, about SAR studies and the possible frontiers for bioactivity data.

Landscape view of emerging contributors, companies, and researchers in the emerging field of exosome research. This article overviews key players in diagnostics and therapeutic fields of exosome research with a deeper look into the current clinical pipeline.

ACE2タンパク質はCOVID-19および他のウイルス感染症の重要な標的であり、この知識は新しい治療法の開発につながりました。

Exosomes could revolutionize drug delivery and diagnostics, but face isolation and purification challenges. This article explores recent trends in exosome research, focusing on their applications in drug delivery, diagnostics, and therapeutics. Discover how these unique particles are shaping the fut

The FDA can designate drug candidates as “breakthrough therapies” (breakthrough therapy designation or BTD) for certain drug candidates that demonstrate substantial improvement over available therapies on a clinically significant endpoint.

Bioorthogonal chemistry is a set of methods that use the chemistry of non-native functional groups to analyze biology in living organisms.

脂質ナノ粒子を探求する：その起源からCOVIDワクチン、そして将来の応用まで。各種論文とマイルストーンにおける新たなトレンドを見てみましょう。ワクチン、薬物送達、農芸化学、化粧品、食品科学などの非治療分野における将来の応用を探ります。これらの粒子がどのように形成されているかをご覧ください。

Learn more about cytokine storms and their role in both immunity and severe infection with COVID-19 and additional viral infections. This overviews emerging trends and insights on publications, milestones, and future applications to minimize the impact of cytokine adverse effects.

Expert panelists include Dr. Benjamin Ebert, the chair of Medical Oncology at the Dana-Farber Institute, Dr. Phil Chamberlain, the co-founder, President, and CEO of Neomorph, and Janet Sasso, an information scientist specializing in Life Sciences at CAS.

When mRNA (messenger RNA) vaccines are injected into a patient, tiny lipid vesicles transport mRNA molecules through the body fluids and merge with immune cells, called antigen-presenting cells (APCs).

Find out how companies improve their prediction accuracy, obtain Breakthrough Technology Status and shorten the development and review time of new drugs by leveraging CAS advanced machine learning methods.

This blog details the recently published CAS indicator of drug innovation based on the structural novelty of new molecular entities (NMEs) which may better assess innovativeness of new drugs.

Scientists are searching ways to stop the spread of COVID-19, and the ACE2 receptor is one of the most promising targets.

Bioorthogonal chemistry is a set of methods using the chemistry of non-native functional groups to explore and understand biology in living organisms.

This insight report explores innovative research and technologies that played crucial roles in Covid-19 vaccine development.

This insight report explores innovative research and technologies that played crucial roles in Covid-19 vaccine development.

人の癌細胞の5分の1にはRAS変異が関わっていると推定されています。かつては薬物治療が不可能だと考えられていましたが、このブログ記事では、RAS阻害剤と新しい治療法の最近の進歩に焦点を当てています。

The COVID pandemic revealed deficiencies in mask development and production. Innovation will be crucial in slowing the spread of new variants of the virus.

As COVID-19 cases rise again worldwide, the Omicron subvariant BA.5 is currently the dominant strain. This blog explores some key mutations that increase transmission, evade protective antibodies, and increase the rate of (re)infection.

Targeted protein degradation is a novel and quickly expanding drug discovery strategy. It is a new way of utilizing disease-causing proteins to attack severe illnesses, which has the potential to be used among more serious illnesses, such as cancer or neurodegenerative diseases.

Artificial intelligence (AI) and machine learning have been growing exponentially over the last decade, but how has the field of Chemistry evolved with this emerging trend?

The use of RNA in therapeutics has the potential to revolutionize medicine. This white paper highlights the emerging trends in the industry.

Lipid nanoparticles play critical roles in mRNA vaccines for treating COVID-19, but their use is not new. Read about past, present, and future opportunities.

The last decade has seen a dramatic shift towards RNA-based medicine. Rapid success in developing lipid-RNA nanoparticles for COVID-19 mRNA vaccines, along with several approved drugs, has propelled RNA to the forefront of pharmaceutical research and development. Explore this revolutionary trend.

This white paper details the CAS Biomedical Knowledge Graph and shows how it was used in drug discovery for COVID-19.

Learn about the important functions of intrinsically disordered proteins and the key role they play in COVID-19 therapy.

This blog lists and discusses the common ingredients (both in the household and scientific contexts) as well as the unique ingredients used in the Covid-19 vaccines currently in use in the United States, and also addresses the dosage levels proposed for children under five years of age.

Omicron's significant evolution from the original COVID-19 virus raises concerns about reinfection and vaccine evasion. This variant could potentially bypass existing immunity, threatening global pandemic recovery efforts. Explore the potential societal and economic impacts of this new challenge.

The COVID-19 pandemic has motivated researchers across the globe to find effective drugs and therapeutics for treating the disease.

In recent years, AI application to chemistry has rapidly grown. While there has been numerous publicity about AI used in this manner, there hasn’t been a lot of in-depth analysis on its use and development in the chemistry field.

Lipid nanoparticles (LNPs) have emerged as promising vehicles to deliver a variety of therapeutics in the pharmaceutical industry. Liposomal drugs, based on an earlier version of LNPs, have already been approved and applied to medical practice.

This report reviews Covid-19 vaccine research, compares the underlying technologies, the use of adjuvants and delivery systems in their application, and provides a perspective on their future direction.

Artificial Intelligence may be hot right now, but the smart money is investing in data. See how CAS solutions can help.

Learn how machine learning procedures and CAS COVID-19 resources, including scientific insights, open access datasets and special reports are assisting in the research to fight against COVID-19.

To identify potential anti-SARS-CoV-2 therapeutics, CAS scientists are building machine-learning predictive models to identify novel drug candidates for the viral targets 3 chymotrypsin-like protease (3CLpro) and RNA-dependent RNA polymerase (RdRp).

In support of ongoing research efforts to identify additional drugs for COVID-19, a team of CAS scientists analyzed published scientific information and created a comprehensive report focusing on proteins involved in COVID-19 and potential corresponding drug candidates.

This report aids COVID-19 therapeutic research by summarizing protein targets and potential drug candidates. It includes bioassay and structure-activity relationship data from scientific and patent literature for COVID-19 and related viral infections. Explore key insights to support ongoing drug dev

A critical step in the race to develop treatments for COVID-19 is to gain a clear understanding of how the virus enters our cells. This insight will support development of targeted antiviral treatments focused on blocking that pathway.

To provide a better understanding and comparison of the diagnostic tests available in the fight against COVID-19, CAS has produced a report summarizing the basic principles of molecular and serological assays being used in diagnostic tests for SARS-CoV-2.

To support R&D on COVID-19, CAS has produced a special report to provide an overview of published scientific information with an emphasis on patents in the CAS content collection.